Please ensure Javascript is enabled for purposes of website accessibility

2 Reasons Intercept Pharmaceuticals Stock Tanked in April

By George Budwell – May 9, 2019 at 9:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Intercept's shares continued to slide last month. Here's why.

What happened

Intercept Pharmaceuticals (ICPT -14.99%), a commercial-stage liver disease specialist, lost a staggering 22.7% of its value in April, according to data from S&P Global Market Intelligence. What caused investors to hit the exits last month?

Intercept's shares broke down in April for two reasons:

  • The raging drug pricing debate in the United States weighed on nearly every biopharma stock last month. Not surprisingly, Intercept's shares proved to be no exception to this downward trend, given the rather hefty price tag for its Food and Drug Administration-approved primary biliary cholangitis drug, Ocaliva. 
  • The company's April update on Ocaliva's pivotal nonalcoholic steatohepatitis (NASH) trial at the International Liver Congress turned out to be a nonevent for the most part. Investors were hoping this update would lay out a stronger case for Ocaliva's label expansion into NASH and subsequent competitive positioning in this jam-packed space. 
A black-and-white chalkboard chart showing a positive trend turning negative.

Image source: Getty Images.

So what

Ocaliva is on track to become the first-ever FDA-approved drug for NASH. While NASH is undeniably a multibillion-dollar commercial opportunity that could cause Intercept's top line to soar in the coming years, the drug's mixed late-stage results for this indication are likely to trigger an advisory committee meeting prior to a formal regulatory decision.

So, Ocaliva's first-mover advantage in NASH is far from a sure thing at this point. The drug's problematic side effect profile also opens the doors for rival NASH therapies from a competitive standpoint. In other words, Ocaliva may never turn out to be the megablockbuster the company and its shareholders originally envisioned. 

Now what

Per the company's first-quarter update, Ocaliva's regulatory application should be in the hands of the FDA by the third quarter of this year. Intercept also plans to file for Ocaliva's NASH indication in the European Union by the fourth quarter of 2019. So, if everything goes according to plan, Intercept could start racking up NASH sales in the second half of 2020. That's an exciting proposition in light of NASH's monstrous commercial opportunity.

However, investors shouldn't underestimate the regulatory risk here. Ocaliva's late-stage NASH trial wasn't a smashing success by any stretch of the imagination, and there are a host of other drugs in development for this indication. The FDA, in turn, may simply decide to wait for a more compelling option for NASH. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends Intercept Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intercept Pharmaceuticals Stock Quote
Intercept Pharmaceuticals
$13.95 (-14.99%) $-2.46

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.